Vertex, once king of hep C category, bows out as new drugs eclipse Incivek

Biotech Vertex ($VRTX) has pulled the plug on work in the hepatitis C arena, an area it was expected to dominate with its Incivek until Gilead Sciences ($GILD) redefined the category with Sovaldi, a drug now expected to become the top seller of all time. Even with Incivek fading away, Vertex has continued work in the area, but yesterday said it would out-license its remaining hep C drug, VX-135, and focus its efforts on cystic fibrosis, FierceBiotech reports. Story | More

Suggested Articles

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.